European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 279, P. 116872 - 116872
Published: Sept. 12, 2024
Language: Английский
Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)
Published: Oct. 10, 2024
Pancreatic cancer remains one of the most aggressive solid tumors. As a systemic disease, despite improvement multi-modality treatment strategies, prognosis pancreatic was not improved dramatically. For resectable or borderline patients, surgical strategy centered on improving R0 resection rate is consensus; however, role neoadjuvant therapy in patients and optimal chemotherapy with without radiotherapy were debated. Postoperative adjuvant gemcitabine/capecitabine mFOLFIRINOX recommended regardless margin status. Chemotherapy as first-line for advanced metastatic included FOLFIRINOX, gemcitabine/nab-paclitaxel, NALIRIFOX regimens whereas 5-FU plus liposomal irinotecan only standard care second-line therapy. Immunotherapy an innovative although anti-PD-1 antibody currently agent approved by MSI-H, dMMR, TMB-high tumors, which represent very small subset cancers. Combination strategies to increase immunogenicity overcome immunosuppressive tumor microenvironment may sensitize immunotherapy. Targeted therapies represented PARP KRAS inhibitors are also under investigation, showing benefits progression-free survival objective response rate. This review discusses current modalities highlights cancer.
Language: Английский
Citations
15
Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)
Published: Dec. 26, 2024
Immune checkpoint inhibitors (ICIs) have dramatically transformed the treatment landscape for various malignancies, achieving notable clinical outcomes across a wide range of indications. Despite these advances, resistance to immune blockade (ICB) remains critical challenge, characterized by variable response rates and non-durable benefits. However, growing research into complex intrinsic extrinsic characteristics tumors has advanced our understanding mechanisms behind ICI resistance, potentially improving outcomes. Additionally, robust predictive biomarkers are crucial optimizing patient selection maximizing efficacy ICBs. Recent studies emphasized that multiple rational combination strategies can overcome enhance susceptibility ICIs. These findings not only deepen tumor biology but also reveal unique action sensitizing agents, extending benefits in cancer immunotherapy. In this review, we will explore underlying ICIs, discuss significance microenvironment (TIME) biomarkers, analyze current outline alternative effectiveness including personalized
Language: Английский
Citations
6
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1500 - 1500
Published: Feb. 11, 2025
The poor prognosis of pancreatic ductal adenocarcinoma (PDAC) is largely due to several challenges, such as late diagnosis, early metastasis, limited response chemotherapy, aggressive tumor biology, and high rates recurrence. Therefore, the development a non-invasive effective method for detection PDAC crucial improving patient outcomes. Continued research exploration in this area are essential enhance methods ultimately improve individuals with PDAC. In study, we examined 37 exosomal surface proteins through multiplex flow cytometry test on peripheral plasma samples from group 51 clinical control (including healthy volunteers non-cancer patients (Cholecystectomy, Hernia, volunteers)), 21 pancreatitis, 48 diagnosed Our findings revealed that level CD40 expression significantly lower pancreatitis compared (p < 0.0001). Additionally, exhibited higher levels CD25 than = 0.0104). exo-CD40 had worse survival 0.0035). Similarly, exo-CD25 showed comparison 0.04). Statistical analysis achieved an AUC 0.827 distinguishing controls. Combining along CA19-9 discriminated controls 0.92. Exo-CD40 found exosomes isolated can serve excellent biomarkers diagnosis Further larger scale studies needed validate combined diagnostic tool identification liquid biopsy.
Language: Английский
Citations
0
Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 715 - 715
Published: Feb. 20, 2025
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with poor prognosis. Currently, chemotherapy the only option for most patients advanced-stage PDAC. Further, conventional immunotherapies and targeted therapies improve survival outcomes in rare PDAC patient subgroups. To date, combinatory immunotherapeutic strategies to overcome immune-hostile tumor microenvironment (TME) have resulted limited efficacy clinical studies. However, efforts are ongoing develop new treatment evolving knowledge of TME, molecular characterization, immune resistance mechanisms. growing arsenal various agents, including novel classes checkpoint inhibitors oncolytic, chimeric antigen receptor T cell, vaccine therapies, reinforces these efforts. This review will focus on place immunotherapy future possible
Language: Английский
Citations
0
The Lancet, Journal Year: 2025, Volume and Issue: 405(10485), P. 1182 - 1202
Published: April 1, 2025
Language: Английский
Citations
0
JCO Oncology Practice, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 26, 2024
Pancreatic adenocarcinoma (PDAC) unfortunately remains a highly fatal disease with 5-year survival rate of only 11%. If surgical resection is not possible, systemic chemotherapy represents the standard-of-care approach to management. Combination regimens using fluorouracil (fluorouracil, oxaliplatin, leucovorin, and irinotecan; fluorouracil, oxaliplatin) or gemcitabine albumin-bound paclitaxel have potential improve overall for patients advanced disease. With increasing understanding molecular drivers pancreatic cancer, novel therapeutic approaches made incremental progress these patients. The landscape PDAC has been studied extensively. Approximately 90% PDACs harbor mutations in KRAS gene, driver mutation that long considered undruggable. However, inhibitors shown promise early-phase clinical trials, larger studies ongoing. Less frequently encountered genomic aberrations include NRG, BRAF, NTRK, HER2, BRCA, PALB2, claudin. Immune checkpoint yielded disappointing efficacy majority except those tumors exhibiting deficiency mismatch repair proteins. Alternative incorporate immunotherapy more such as use immune selected maintenance setting vaccine therapies postsurgery adjuvant setting. It vital perform profiling all identify treatment targets, enroll trials whenever possible.
Language: Английский
Citations
2
The Lancet Oncology, Journal Year: 2024, Volume and Issue: 25(7), P. 824 - 825
Published: June 1, 2024
Language: Английский
Citations
1
Carcinogenesis, Journal Year: 2024, Volume and Issue: 45(11), P. 826 - 835
Published: Nov. 1, 2024
Abstract Pancreatic ductal adenocarcinoma (PDA) is a lethal disease for which remarkable therapeutic resistance the norm. Conventional immunotherapies, like immune checkpoint inhibitors, show limited efficacy in PDA due to remarkably immunosuppressive tumor microenvironment (TME) and systemic inflammation. This review discusses potential of both exogenous situ vaccination strategies overcome these barriers enhance anti-tumor immunity PDA. Exogenous vaccines, including whole-cell, dendritic cell, peptide, nucleic acid-based have shown varying degrees promise but face challenges related antigen selection, production complexities, patient-specific factors. In contrast, leverage conventional cytotoxic therapies, such as chemotherapy radiation therapy, induce immunogenic cell death modulate TME with aim stimulate immunity. While preclinical studies support use vaccination, balancing stimulatory inhibitory effects likely fundamental eliciting productive responses patients. Ongoing research seeks identify new innovative that can harness endogenous response trigger vaccination. Overall, while approaches offer significant potential, further clinical trials will be needed optimize improving patient outcomes
Language: Английский
Citations
1
European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 279, P. 116872 - 116872
Published: Sept. 12, 2024
Language: Английский
Citations
0